The market leader behind the 3D Mammography exam, Hologic has announced the granting of a CE Mark to their LOCalizer wireless radio frequency identification (RFID) breast lesion localization system. The system is designed for precise and easy marking and targeting of lesions for breast-conserving surgery guidance.
The LOCalizer tag is designed to replace the traditional wire-guided localization method, helping to provide increased comfort and convenience for patients and their healthcare teams. The tag can be implanted up to 30 days prior to a breast-conserving surgery, providing increased flexibility for patients and providers. This improved workflow is designed to help reduce scheduling and logistical hurdles for care teams and aims to deliver added convenience for an enhanced patient experience. Following placement, the miniature implantable tag can be detected by a portable, handheld reader that indicates the location and distance in millimeters to the lesion, enabling the surgeon to pinpoint the correct area of breast tissue for removal.
Hologic has expanded significantly in recent years through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast health. Along with the LOCalizer system, the company’s new products include the SmartCurve breast stabilization system, Clarity HD high-resolution 3D imaging technology, the Viera portable breast ultrasound system, and the Brevera breast biopsy system with CorLumina imaging technology, which features real-time imaging and sample verification.
Marlborough, MA, USA